Current Report Filing (8-k)
May 03 2021 - 9:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 3, 2021
AIKIDO PHARMA INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
000-05576
|
|
52-0849320
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
One Rockefeller Plaza, 11th Floor, New York, NY
|
|
10020
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
Registrant’s telephone number, including area code: (703) 992-9325
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.0001 par value
|
|
AIKI
|
|
The Nasdaq Capital Market
|
Item 8.01 Other Events.
On May 3, 2021, AIkido Pharma
Inc., a Delaware corporation (the “Company”), issued a presentation deck (the “Presentation”) summarizing the
Company’s current drug products.
Item 9.01. Financial Statements and Exhibits
d) Exhibits.
The exhibit listed in the
following Exhibit Index is filed as part of this Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AIKIDO PHARMA INC.
|
|
|
|
By:
|
/s/ Anthony Hayes
|
|
Name:
|
Anthony Hayes
|
|
Title:
|
Chief Executive Officer
|
Dated: May 3, 2021
2
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Sep 2023 to Sep 2024